Status
Conditions
Treatments
About
Retrospective study of the data reported in the Obalon US Commercial Registry
Full description
Retrospective analyses of the safety and effectiveness data in the Obalon US Commercial Registry reported by participating clinics through August 28, 2018 from patients who started the Obalon therapy from January to December 2017 to represent the first year of commercialization. All patients included in the safety and efficacy analyses must have data through balloon removal and a starting BMI greater than or equal to 25, the definition of overweight and obese patients.
Enrollment
Sex
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal